Business Insights | HPC, Life Sciences and AI: Powering the Next Wave of Scientific Innovation

The convergence of big data, Artificial Intelligence (AI), and high performance computing (HPC) in life sciences is transforming the sector. From accelerating drug discovery process to enabling precision medicine and advanced genomics, digital infrastructure is now as critical to R&D as laboratory space itself.

As life sciences organisations compete to bring therapies to market faster, the demand for AI ready data centre capacity, secure digital environments and scalable HPC life sciences infrastructure is growing. High-Performance Computing has become an indispensable pillar of modern life sciences and laboratory information technology.

Pharmaceutical companies, biotech firms, CROs and research institutions are under growing pressure to reduce time to market, scale data-intensive research and protect high-value intellectual property. As AI adoption accelerates, the ability to access AI-ready data center capacity, high-density power, advanced cooling and secure, compliant environments is becoming a defining factor in competitive advantage.

For many organisations, AI infrastructure is no longer keeping pace with ambition. This article explores how AI, high performance computing (HPC) and digital infrastructure are transforming life sciences R&D and what organisations must do to overcome capacity constraints, security risks and regulatory complexity.

How is Big Data, AI and High‑Performance Computing Transforming Life Sciences?

The life sciences industry generates unprecedented volumes of data. Genomic sequencing, clinical trials, medical imaging, real world evidence and molecular simulations produce datasets measured in petabytes. Extracting value from this data requires more than storage. It depends on an ecosystem of infrastructure capabilities, including scalable HPC environments, AI-optimised compute, high-throughput storage, ultra-low latency connectivity and secure data centre operations.

Together, these components form the foundation of modern, AI-enabled R&D.

Successfully deploying AI and HPC strategy in life sciences depends on a combination of power availability, cooling capability, connectivity, security, regulatory compliance and long‑term scalability. Establishing strong data governance and workflow management before implementing HPC projects is essential to manage large datasets effectively, and prevent costly mistakes.

AI‑Driven Acceleration of Drug Discovery and Research

AI and machine learning are reshaping life sciences R&D. In the drug discovery process, AI models can analyse molecular structures, predict protein folding and simulate compound interactions in a fraction of the time traditional methods require. HPC systems in life sciences environments accelerate these processes by enabling parallel computation across thousands of processing cores, dramatically reducing development timelines.

In clinical research, AI driven analytics optimise trial design, identify patient cohorts and enhance predictive modelling. Real time data processing improves trial efficiency and increases the probability of regulatory success. Meanwhile, precision medicine relies on HPC powered genomic analysis to tailor treatments to individual patients, unlocking better outcomes and cost efficiencies.

The integration of AI and HPC systems also supports advanced biologics manufacturing, supply chain optimisation and drug safety monitoring. As therapies become more personalised and biologically complex, computing requirements increase dramatically to model the interaction permutations.

Why Are AI Workloads Driving New Infrastructure Intensity?

Power Density and Cooling Requirements

Life science and R&D computational workloads are highly power intensive. AI model training, particularly large language models and deep learning systems, requires technology with very high power density, advanced cooling solutions and low latency network connectivity. Traditional enterprise IT and on-premises infrastructure is now unsuitable to support these requirements.

Network Performance and Latency Sensitivity

For life sciences organisations, access to scalable AI and HPC infrastructure is essential and key to retaining competitive advantage. The ability to process large datasets securely and efficiently directly influences speed to discovery, regulatory approval and commercialisation. Cloud supercomputing enables organisations to meet the growing computational demands of research and biotech, providing flexible and powerful resources for high-performance computing workloads.

The choice of data centre location, power availability, connectivity and regulatory environment now plays a central role in enabling scientific innovation. Managing hot data on high-speed storage tiers, such as flash or in-memory databases, is critical to ensure rapid analysis and low latency in research workflows like cryo-electron microscopy and genomics.

How Can Life Sciences Organisations Protect Data, IP and Patient Privacy?

Intellectual Property

Intellectual property (IP) is the lifeblood of the life sciences industry. Drug formulas, molecular designs, clinical data and proprietary algorithms represent billions in research investment and long-term enterprise value.

Security Requirements

Life sciences organisations face a dual security challenge, safeguarding against both physical and cyber threats. Today most AI and HPC environments operate within specialist highly secure data centres with robust physical security, access controls, redundancy and resilience. At the same time, rigorous cyber security frameworks defend against increasingly sophisticated attacks targeting sensitive research data.

Regulatory Compliance and Data Sovereignty

For some developments data sovereignty is also important. Regulatory requirements often mandate that clinical and patient data remain within specific jurisdictions. Ensuring that data resides within sovereign boundaries mitigates compliance risk and protects against geopolitical uncertainty.

For life sciences companies operating globally, complying with multiple regulatory frameworks is complex. Secure, compliant and resilient data centre environments are foundational to maintaining trust, protecting IP and safeguarding innovation pipelines.

How Are Infrastructure Constraints Impacting R&D Enablement in Life Sciences?

As demand for AI accelerates, access to suitable infrastructure is becoming increasingly constrained. Competition for AI ready data centre capacity, particularly facilities offering high power density and advanced cooling, has intensified across global markets.

Hyperscale cloud providers and AI driven enterprises are absorbing significant capacity, limiting availability for life sciences organisations seeking colocation solutions. Finding AI ready facilities with sufficient power, scalability and network connectivity is challenging, particularly in established European and North American markets.

As a result, R&D enablement is at risk of being hampered by infrastructure bottlenecks. Delays in securing suitable HPC solutions can slow drug discovery programmes, clinical research initiatives and time to market objectives.

For life sciences companies, digital infrastructure planning must now begin well in advance of computational demand. Strategic site selection, capacity forecasting and flexible colocation agreements are critical to maintaining research momentum. HPC solutions can significantly reduce project times for genomic sequencing and structural biology workflows, making timely access critical for pharmaceutical research and structural biology applications.

How Can CBRE Help Life Sciences Organisations Overcome AI and HPC Infrastructure Challenges

Navigating the needs of life sciences innovation and digital infrastructure change requires specialist expertise. Engaging a strategic real estate and infrastructure partner is essential to overcoming market constraints and accelerating acquisition and deployment.

CBRE supports life sciences organisations across the full spectrum of digital infrastructure requirements.

Global AI Data Centre Capacity Advisory

CBRE’s global network provides visibility into available AI ready data centre capacity across key markets. By leveraging deep operator relationships and market intelligence, CBRE helps clients identify suitable colocation solutions aligned with power, cooling and connectivity requirements.

Data Centre Site Selection and Development

For organisations seeking to develop bespoke HPC expertise, CBRE identifies optimal sites with access to sufficient power, renewable energy sources and robust fibre connectivity. Site selection considers grid resilience, sustainability objectives, tax incentives and regulatory compliance, ensuring long term scalability and operational security.

Transaction Advisory and Risk Mitigation

Securing data centre capacity is a complex, capital intensive process. CBRE advises life sciences companies through lease negotiations, power procurement, technical due diligence and contract structuring. This ensures flexibility, cost optimisation and alignment with evolving AI workloads.

Integrated Real Estate and Data Centre Strategy

Importantly, CBRE bridges the gap between laboratory, office and digital infrastructure requirements, aligning physical R&D environments with advanced computing capabilities. This integrated approach enables life sciences organisations to scale innovation efficiently and securely.

As AI and HPC solutions reshape the scientific landscape, proactive infrastructure strategy can be a clear differentiator. Partnering with an experienced advisor reduces risk, accelerates deployment and ensures access to the digital infrastructure required for sustained innovation.

Conclusion

AI and HPC solutions are redefining the future of life sciences. From accelerating drug discovery to enabling precision medicine, digital infrastructure is central to scientific advancement. Yet growing competition for AI ready data centre capacity, combined with heightened security and regulatory demands, presents significant challenges.

By aligning real estate strategy with HPC and AI requirements, and partnering with an expert advisor, life sciences organisations can secure the infrastructure needed to innovate at pace, protect intellectual property and deliver transformative therapies to market.